Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.
Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, Schmid P, Loi S, Sunpaweravong P, Musolino A, Li H, Zhang Q, Nowecki Z, Leung R, Thanopoulou E, Shankar N, Lei G, Stout TJ, Hutchinson KE, Schutzman JL, Song C, Jhaveri KL. Turner NC, et al. Among authors: juric d. N Engl J Med. 2024 Oct 31;391(17):1584-1596. doi: 10.1056/NEJMoa2404625. N Engl J Med. 2024. PMID: 39476340 Clinical Trial.
Financial toxicity in early-phase cancer clinical trial participants.
Durbin SM, Lundquist D, Pelletier A, Petrillo LA, Bame V, Turbini V, Heldreth H, Lynch K, Boulanger M, Lam A, McIntyre C, Ferrell BR, Jimenez R, Juric D, Nipp RD. Durbin SM, et al. Among authors: juric d. Cancer. 2024 Oct 10. doi: 10.1002/cncr.35586. Online ahead of print. Cancer. 2024. PMID: 39387163
A unique interplay of access and selection shapes peritoneal metastasis evolution in colorectal cancer.
Wassenaar EC, Gorelick AN, Hung WT, Cheek DM, Kucukkose E, Lee IH, Blohmer M, Degner S, Giunta P, Wiezer RM, Raicu MG, Ubink I, Klaasen SJ, Lansu N, Watson EV, Corcoran RB, Boland G, Getz G, Kops GJ, Juric D, Lennerz JK, Boerma D, Kranenburg O, Naxerova K. Wassenaar EC, et al. Among authors: juric d. bioRxiv [Preprint]. 2024 Sep 27:2024.09.25.614736. doi: 10.1101/2024.09.25.614736. bioRxiv. 2024. PMID: 39386634 Free PMC article. Preprint.
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
Jhaveri KL, Accordino MK, Bedard PL, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K, Krop IE, Oliveira M, Schmid P, Saura C, Turner NC, Varga A, Cheeti S, Hilz S, Hutchinson KE, Jin Y, Royer-Joo S, Peters U, Shankar N, Schutzman JL, Juric D. Jhaveri KL, et al. Among authors: juric d. J Clin Oncol. 2024 Sep 5:JCO2400110. doi: 10.1200/JCO.24.00110. Online ahead of print. J Clin Oncol. 2024. PMID: 39236276
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment.
O'Connell BC, Hubbard C, Zizlsperger N, Fitzgerald D, Kutok JL, Varner J, Ilaria R Jr, Cobleigh MA, Juric D, Tkaczuk KHR, Elias A, Lee A, Dakhil S, Hamilton E, Soliman H, Peluso S. O'Connell BC, et al. Among authors: juric d. J Immunother Cancer. 2024 Aug 30;12(8):e009160. doi: 10.1136/jitc-2024-009160. J Immunother Cancer. 2024. PMID: 39214650 Free PMC article. Clinical Trial.
Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets.
Vijay V, Karisani N, Shi L, Hung YH, Vu P, Kattel P, Kenney L, Merritt J, Adil R, Wu Q, Zhen Y, Morris R, Kreuzer J, Kathiresan M, Herrera Lopez XI, Ellis H, Gritti I, Lecorgne L, Farag I, Popa A, Shen W, Kato H, Xu Q, Balasooriya ER, Wu MJ, Chaturantabut S, Kelley RK, Cleary JM, Lawrence MS, Root D, Benes CH, Deshpande V, Juric D, Sellers WR, Ferrone CR, Haas W, Vazquez F, Getz G, Bardeesy N. Vijay V, et al. Among authors: juric d. bioRxiv [Preprint]. 2024 Jul 8:2024.07.04.601970. doi: 10.1101/2024.07.04.601970. bioRxiv. 2024. PMID: 39026794 Free PMC article. Preprint.
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.
Pearson AD, DuBois SG, Macy ME, de Rojas T, Donoghue M, Weiner S, Knoderer H, Bernardi R, Buenger V, Canaud G, Cantley L, Chung J, Fox E, Friend J, Glade-Bender J, Gorbatchevsky I, Gore L, Gupta A, Hawkins DS, Juric D, Lang LA, Leach D, Liaw D, Lesa G, Ligas F, Lindberg G, Lindberg W, Ludwinski D, Marshall L, Mazar A, McDonough J, Nysom K, Ours C, Pappo A, Parsons DW, Rosenfeld A, Scobie N, Smith M, Taylor D, Weigel B, Weinstein A, Karres D, Vassal G. Pearson AD, et al. Among authors: juric d. Eur J Cancer. 2024 Aug;207:114145. doi: 10.1016/j.ejca.2024.114145. Epub 2024 Jun 8. Eur J Cancer. 2024. PMID: 38936103 Free article. Review.
The glutathione S-transferase Gstt1 drives survival and dissemination in metastases.
Ferrer CM, Cho HM, Boon R, Bernasocchi T, Wong LP, Cetinbas M, Haggerty ER, Mitsiades I, Wojtkiewicz GR, McLoughlin DE, Aboushousha R, Abdelhamid H, Kugel S, Rheinbay E, Sadreyev R, Juric D, Janssen-Heininger YMW, Mostoslavsky R. Ferrer CM, et al. Among authors: juric d. Nat Cell Biol. 2024 Jun;26(6):975-990. doi: 10.1038/s41556-024-01426-7. Epub 2024 Jun 11. Nat Cell Biol. 2024. PMID: 38862786
Time Toxicity Experienced by Early-Phase Cancer Clinical Trial Participants.
Durbin SM, Lundquist DM, Pelletier A, Jimenez R, Petrillo L, Kim J, Lynch K, Healy M, Johnson A, Ollila N, Yalala V, Malowitz B, Kehlmann A, Chevalier N, Turbini V, Bame V, Heldreth H, Silva J, McIntyre C, Juric D, Nipp RD. Durbin SM, et al. Among authors: juric d. JCO Oncol Pract. 2024 Sep;20(9):1252-1262. doi: 10.1200/OP.23.00811. Epub 2024 Jun 10. JCO Oncol Pract. 2024. PMID: 38857457
178 results